DNTH
Dianthus Therapeutics Inc.
88.60$
-2.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -50.5% | +91.2% | +113.2% | +16.6% | -39.0% | -12.3% | -83.4% | +105.2% | -28.3% | +63.0% | +64.4% | – | |
| – | +442.1% | +3.9% | +3.7% | +4.5% | -32.8% | +70.5% | -25.6% | +0.0% | – | – | – | – | |
| – | -49.5% | +91.2% | +113.2% | +16.6% | -39.0% | -12.3% | -83.4% | +105.2% | -28.3% | +36.3% | +96.6% | – | |
| – | +10.3% | +48.9% | +38.2% | +41.4% | +3.4% | +2.2% | -2.8% | +23.8% | +84.4% | -42.4% | +41.0% | – | |
| – | -46.9% | +21.8% | +6.3% | +8.9% | +4.6% | +7.4% | +20.9% | -7.6% | +21.2% | +25.6% | +8.7% | – | |
| – | -19.5% | +39.6% | +28.6% | +33.3% | +3.6% | +3.3% | +2.3% | +15.8% | +71.6% | -32.8% | +32.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -141.7% | – | – | |
| – | – | -112.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -141.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -141.5% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.